Florida Hospital Acquires Transenterix Inc (NYSEAMERICAN:TRXC) Senhance Surgical Robotic System


Medical device company Transenterix Inc (NYSEAMERICAN:TRXC) has revealed that Florida Hospital has agreed to acquire the firm’s Senhance Surgical Robotic System. The Orlando campus of Florida Hospital will thus become the first healthcare institution in the United States to have the system installed at its facilities.

“We are pleased to announce our first US sale of the Senhance Surgical System. Florida Hospital is a global leader in the application of next generation technologies to care for patients,” TransEnterix’s chief executive officer and president, Todd M. Pope, said.

FDA Approval

The Senhance Surgical System was recently approved by the U.S. Food and Drug Administration and is an innovative technology developed to help surgeons to perform minimally invasive surgery. Among the features of the system includes multiple robotic arms which are under the control of a surgeon using a console. Thus small surgical instruments are controlled by the surgeon with robotic precision. During this time a small scope is used to track the surgeon’s eye movements.

This surgical system is the first robotic system to provide haptic force feedback and this lets the surgeons feel how much force is being generated by the instruments when delicate tissue is being handled. With this new system a hospital is able to achieve the standards that are set by the value-based healthcare code of modern times.

Invasiveness of surgery

At the time of getting the approval from the FDA about a month ago Pope indicated that the robotic system would improve the value, efficacy and choices that patients, hospitals and surgeons are presented with. According to Pope the tools that were previously available to surgeons were limiting the comfort, control and capability of surgeons but the Senhance system would not only afford surgeons what they were lacking but would also reduce the invasiveness of surgery and thus offering better patient outcomes and value maximization for hospitals.

Senhance was acquired by TransEnterix from an Italian firm known as Sofar two years ago. Across Europe the robotic surgical system has receive the CE Mark of approval. In Europe each robotic system is sold at a price of $2 million.

On Monday shares of Transenterix Inc shot up by 11.54% to close the day at $3.19 a share.


Please enter your comment!
Please enter your name here